Vicriviroc or SCH 417690 is a potent and selective antagonist of the CCR5 receptor. CCR5 receptor antagonists have the potential for the treatment of HIV infections. Four distinct isotopically labelled forms of SCH 417690 were synthesized. Low specific activity [H-3]SCH 417690 was prepared for a preliminary absorption, distribution, metabolism and excretion evaluation of the compound and [C-14]SCH 417690 for more definitive absorption, distribution, metabolism and excretion work, including an absorption, metabolism and excretion study in man. In addition, high specific activity [H-3]SCH 417690 was prepared for CCR5 receptor binding work and [H-2(4)]SCH 417690 was prepared as an internal standard for a liquid chromatography-mass spectrometry bioanalytical method. The paper discusses the synthesis of four isotopically labelled forms of SCH 417690.
Synthesis of H-3, H-2(4) and C-14-SCH 417690 (Vicriviroc)
Hesk, D., Borges, S., Hendershot, S., Koharski, D., McNamara, P., Ren, S., Saluja, S., Truong, V., & Voronin, K. (2016). Synthesis of H-3, H-2(4) and C-14-SCH 417690 (Vicriviroc). Journal of Labelled Compounds and Radiopharmaceuticals, 59(5), 190-196. https://doi.org/10.1002/jlcr.3387
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Use of a web-based portal to return normal individual research results in Early Check
The importance of quality data to track global progress in addressing stillbirths and neonatal mortality